The company focuses on developing pharmaceuticals for oncology and neurology, specifically targeting neurodegenerative conditions such as Alzheimer's, Parkinson's, and other dementia-related diseases. In addition, Eisai Europe also develops drugs for solid tumors. Their goal is to provide products and services that improve the health of their patients.